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Theaimofthisstudyistoevaluateironstatus,erythrocyte,andplateletmodiﬁcationsindogswithchronicenteropathy(CE).Dogs
were grouped as food-responsive diarrhea (FRD, n = 11), antibiotic-responsive diarrhea (ARD, n = 5), and steroid-responsive
diarrhea (SRD, n = 6) relating to therapeutic-response. Clinical and haematological ﬁndings, evidence of gastrointestinal blood
loss,andironmetabolismwereevaluatedbeforeandaftertreatment.Amildnormocyticormicrocyticanemiaandthrombocytosis
were identiﬁed, respectively in 18.0% and 31.8% of CE dogs. No signiﬁcant diﬀerences between pre- and posttreatment of
hematocrit, haemoglobin, and mean corpuscular volume, platelet count and mean platelet volume were found. Statistical analysis
pointed out signiﬁcant diﬀerences between pre- and posttreatment in serum iron (P<. 03) and unsaturated iron binding capacity
(UIBC) (P<. 01). No signiﬁcant correlations were found between these parameters and canine Inﬂammatory Bowel Disease
activity index and pattern of CE as well.
1.Introduction
Diﬀerent hematologic abnormalities are often observed in
human patients with inﬂammatory bowel disease (IBD).
Anemia is a frequent ﬁnding in ulcerative colitis (UC)
and Crohn’s disease (CD), with reported rates varying
between 30% and 50%, respectively. Iron deﬁciency is the
most common cause of anemia in IBD, particularly due
to occult chronic gastrointestinal (GI) blood loss. The
increased epithelial sloughing in chronic GI inﬂammation
may increase the iron loss. Anemia of chronic disease (ACD)
is frequently related to iron deﬁciency anemia (IDA) in IBD
patients[1,2].TheACDisaconsequenceofcytokinesactiva-
tion (i.e., tumor necrosis factor alpha [TNF-α], interleukin-
1 [IL-1], interferon [IFN]) and synthesis of acute phase
proteins [1, 2]. Reduced half-life of erythrocytes, decreased
erythropoietin synthesis, and reduced bioavailability of iron
are the pathophysiological mechanisms involved in ACD [3].
Immune thrombocytopenic purpura is rarely reported
in human patients with IBD. The same immunological
events that lead to intestinal inﬂammation are hypothesized
to cause also platelets destruction and both abnormalities
resolve with treatment [4]. Moreover, thrombocytosis may
occur in IBD and probably represents a nonspeciﬁc response
to the inﬂammation. An elevated platelet count in human
medicine is a well-known recognized marker of IBD activity
as thrombopoietin levels are signiﬁcantly elevated [5, 6]. In
addition, iron deﬁciency is a cause of reactive thrombocy-
tosis, although further investigations will be necessary to
elucidate the pathogenetic mechanism [7].
Few reports are available regarding the haematologi-
cal aspects in canine chronic enteropathy (CE). Ridgway
and others [8] reported thrombocytopenia, often with
macroplatelets, in seven dogs with IBD; thrombocytopenia
appears to be subclinical and in some cases resolved with
therapy. No correlation between histopathological severity of
inﬂammation and degree of thrombocytopenia was found.
Ristic and Stidworthy [9]d e s c r i b e das e v e r em i c r o c y t i c
anemia with moderate regeneration and low serum iron
concentration,intwodogswithchronicbloodlossassociated
to CE. Craven and others [10], in a retrospective study
on 80 cases of canine IBD, reported the incidence of2 Veterinary Medicine International
some haematological abnormalities, such as anemia (12%),
thrombocytosis (7%), and thrombocytopenia (13%). The
authors hypothesized an association of these abnormalities
and IBD.
Furthermore, to the authors’ best knowledge, investi-
gations about serum iron proﬁle in dogs with CE were
not performed. The purpose of this prospective study was
to evaluate erythrocyte, platelet, and iron abnormalities
observed in dogs with CE.
2.MaterialsandMethods
2.1. Clinical Cases. Over a 12-month period, 22 dogs (8
femalesand14males)withclinicalsignsofCEwereincluded
in the prospective treatment trial. Selection criteria for cases
included a history of chronic diarrhea with or without
vomiting of at least 4 weeks duration (mean 10.3 + 6
weeks), histopathologic evidence of intestinal inﬂammatory
cellularinﬁltration,andabsenceofunderlyingextraintestinal
disorders. Laboratory data performed to rule out underlying
disorders included complete blood count (CBC), serum
biochemical proﬁle, urinalysis and fecal samples analysis
for common parasites and Giardia spp. (SNAP Giardia,
Idexx Laboratoires, Milan, Italy). Additional tests included
assessmentoftrypsin-likeimmunoreactivity,cobalamin,and
folate serum concentrations, and abdominal bi-dimensional
ultrasoundexamination.Thedogs’agerangedfrom1.4to12
yearsold(mean4.8+3.4years,median3.5years)andseveral
breeds and mixed breeds of dogs were represented.
All dogs were classiﬁed according to the canine IBD
activity index (CIBDAI) scoring system, established by
Jergensandothers[11],whichisbasedonsixgastrointestinal
signs: general attitude and activity, appetite, vomiting, stool
consistency, stool frequency, and weight loss. The total
composite score is determined to be clinically insigniﬁcant
(score0–3), mild (score4-5), moderate (score6–8), orsevere
( s c o r e9o rg r e a t e r ) .
A sequential trial therapy approach with an elimination
diet, antibiotics, and immunosuppressive treatment as a
last resort, according to other authors [12]w a sp e r f o r m e d .
Initially, all dogs were treated with an elimination diet
(Purina HA, Nestl´ e Purina, Udine, Italy) for 10 days. Dogs
respondingtotheeliminationdietintheﬁrst10days(clinical
signs improved or resolved) were assigned to the food-
responsive diarrhea (FRD) group. Dogs that did not respond
in the ﬁrst 10 days of treatment (clinical signs persisted while
on the elimination diet), an antibiotic treatment with tylosin
(20mg/kg Body Weight [BW] q12h per os [PO] for 4 weeks)
was administered. If a positive response to both treatments
improvesorresolvesthesymptoms,dogswereassignedtothe
antibiotic-responsivediarrhea(ARD)group.Indogsthatdid
not respond to antibiotic therapy, oral prednisolone without
any antibiotic support was given (1mg/kg BW q12h PO
for 20 days followed by a tapering dosage over 6–8 weeks)
and these patients were assigned to the steroid-responsive
diarrhea (SRD) group. All dogs were fed continuously with
elimination diet for 12 weeks.
At the time when diagnosis was postulated and when
clinical signs were improved or resolved, a CBC (HecoVet,
Florence, Italy) with reticulocyte count (LaserCyte Idexx
Laboratories, Milan, Italy and manual count with new
methylene blue; the results obtained were overlapping each
other)wasperformed.Theserumironproﬁleincludingiron,
ferritin, unsaturated iron binding capacity (UIBC), related
calculation of total iron binding capacity (TIBC), and trans-
ferrin saturation percentage, together with the measurement
of C-reactive protein concentration were performed with
Olympus AU2700 chemistry-immuno system and using the
supplied reagents (Olympus Italia srl, Segrate, Milan, Italy).
In addition, the fecal occult blood test (HemoFec, Roche
Diagnostics GmbH, Mannheim, Germany) was also carried
out. All dogs tested for fecal occult blood underwent to three
days meat restriction. Moreover, each clinical sign recorded
and body weight were evaluated and scored.
2.2. Statistical Analysis. Normally distributed data are
reported as mean + standard deviation and paired Student’s
t-test was used to analyze the diﬀerences between data at
diagnosis and aftertreatment.A one-wayanalysisof variance
( A N O V A )a n dT u k e yt e s tw e r eu s e dt oe v a l u a t ed i ﬀerences
among groups of dogs (FRD, ARD, and SRD). Correlations
were evaluated with the Spearman correlation test. Statistical
signiﬁcance was set at P < .05.
3. Results
3.1. Clinical Findings. Eleven/22 dogs (50%) were assigned
to FRD group, 5/22 dogs (22.7%) to ARD group, and 6/22
dogs (27.3%) to SRD group. Six dogs had a clinically not
signiﬁcant disease, 7 had mild, 7 moderate, and 2 severe
clinical disease according to the activity index of Jergens
and others (2003). The CIBDAI was signiﬁcantly higher (P
< .05) before treatment in SRD group (7.17 + 2.8) compared
with the FRD (5.4 + 3.2) and ARD (4.6 + 2.07) groups.
After treatment, symptoms were completely resolved in 10
dogs (5/7, 2/5, and 3/6 dogs, respectively in FRD, ARD, and
SRD group). The average value of CIBDAI in dogs before
treatment was 5.72 + 2.91 and at the end of therapy (ranging
time from 1 month to 6 months) was 0.86 + 0.99. The
reductioninaverageactivityindexwasstatisticallysigniﬁcant
(P < .001).
3.2.ErythrocyteFindings. At the time ofdiagnosis andbefore
treatment, a mild normocytic or microcytic anemia was
identiﬁed in 4/22 dogs (18% of cases; hematocrit, Hct
34.9 + 2.2%, reference range 37.0–55.0%; mean corpuscular
volume, MCV 61.7 +/− 3.3fL, reference range 60.0–76.0fL),
while microcytosis without anemia was present in 6/22 dogs
(27.2%; MCV 58.2 + 0.8fL); in 2 of these dogs, positive
fecal occult blood test was found. Common ﬁndings were
anisocytosis (59.0%), polychromasia (40.9%), and Howell-
Jolly bodies (13.6%) that were present also at posttreatment
evaluation (54.5%, 27.3%, and 4.5%, resp.). At posttreat-
ment time, anemia was identiﬁed in 2/22 (9%; mean Hct
35.0 + 0.1%) of dogs, and one dog with microcytosis wasVeterinary Medicine International 3
Table 1: Erythrocyte and platelet modiﬁcations pre- and posttreat-
ment.
Test
(units)
Reference
Range
Pretreatment Posttreatment P
Hct (%) 37–55 44.4 + 6.5 45.4 + 6.0 .636
Hb (g/dL) 12–18.5 15.8 + 2.2 16 + 1.9 .801
MCV (fL) 60–76 63.0 + 2.9 64.2 + 2.8 .180
Reticulocytes
(×109/L) <60.0 39.4 + 18.8 37.5 + 13.9 .736
PLT
(×109/L) 150–400 356.2 + 135.7 324.6 + 101.9 .390
MPV (fL) 7.9–12 10.2 + 1.2 10.3 + 1.0 .947
Hct, hematocrit; Hb, hemoglobin; MCV, mean cell volume; PLT, platelets;
MPV, mean platelet volume.
still occurring. No signiﬁcant diﬀerences between pre- and
posttreatment in Hct. hemoglobin, MCV, and reticulocytes
were found (Table 1). These parameters were not related
with CIBDAI and no statistically signiﬁcant diﬀerences were
found between FRD, ARD, and SRD groups.
3.3. Fecal Blood Test. The fecal occult blood test was positive
in 4/22 of dogs. In one of these dogs, reticulocytosis (72.2
× 109/L, reference range, <60.0 × 109/L) and erythrocytosis
(9.1 × 1012/L; reference range, 5.0–7.9 × 1012/L) were
associated. In addition, another dog had erythrocytosis (8.1
× 1012/L) and one reticulocytosis (91.9 × 109/L). None of
these four dogs showed anemia.
3.4. Serum Iron Proﬁle. Only in one dog with FRD negative
for fecal blood test, low serum iron (45μg/dL, reference
range 81–220μg/dL), low transferrin saturation percentage
(17.5%, reference range 25–52%), and concurrent mild
normocytic anemia (Hct 32%, MCV 62fL) were found. Iron
deﬁciency resolved with symptoms (posttreatment serum
iron 184μg/dL, transferrin saturation percentage 49.3%).
Serum ferritin was increased in 2/22 (9%) dogs (226 +
1.41ng/mL, reference range 60–190ng/mL) and TIBC was
low in 4/22 (18%) dogs (222.7 + 28.7μg/dL; reference range
270–460μg/dL). Statistical analysis identiﬁed signiﬁcant dif-
ferences between pre- and posttreatment in serum iron and
UIBC as well as TIBC, although transferrin saturation and
ferritin did not show any signiﬁcant diﬀerences between
pre- and posttreatment evaluations (Table 2). No signiﬁcant
correlationwasfoundbetweentheseparametersandCIBDAI
or CE pattern.
3.5. Serum CRP Concentration. Serum CRP was increased in
15 of 22 dogs (68.2%) before treatment (0.42 + 0.38mg/dL;
reference range 0–0.15mg/dL) and in 8 (35.4%) after
treatment (0.59 + 0.51mg/dL). Serum CRP concentration
showed no signiﬁcant diﬀerences between pre- and post-
treatment evaluations (Table 2) and did not correlate with
CIBDAI and CE pattern.
Table 2: Serum iron proﬁle and CRP modiﬁcation pre- and
posttreatment.
Test
(units)
Reference
Range
Pretreatment Posttreatment P
Iron (μg/dL) 81–220 129.2 + 34.8 166.0 + 64.8 .030
UIBC (μg/dL) 150–300 208.1 + 48.9 258.5 + 80.5 .010
TIBC (μg/dL) 270–460 337.3 + 64.7 424.5 + 105.9 .001
Transferrin
saturation (%) 25–52 38.5 + 8.5 39.2 + 9.9 .820
Ferritin
(ng/mL) 60–190 116.9 + 45.5 118.1 + 48.9 .931
CRP (mg/dL) 0.0–0.15 0.31 + 0.02 0.26 + 0.39 .703
UIBC, unsaturated iron binding capacity; TIBC, total iron binding capacity;
CRP, C-reactive protein.
3.6. Platelet Findings. Seven of 22 (31.8%) dogs had throm-
bocytosis at presentation (510.4 + 127.9 × 109/L; refer-
ence range, 150–400 × 109/L). Thrombocytopenia was not
observed in any case. At posttreatment evaluation, thrombo-
cytosis was identiﬁed in ﬁve (22.7%) dogs (mean PLT 476.8
+ 63.8 × 109/L). No signiﬁcant diﬀerences between pre-
and posttreatment platelet count and mean platelet volume
(MPV) were found (Table 1). No signiﬁcant diﬀerences
were found in serum iron concentration between dogs
with thrombocytosis (133.3 + 33.7μg/dL, reference range
81–220μg/dL) and those with platelets normal number
(162.2 +/− 54.8μg/dL). No signiﬁcant correlation was found
between the platelet count and both the CIBDAI or CE
pattern.
4. Discussion
In human medicine, hematological aspects of IBD and mod-
iﬁcations of iron metabolism raise up great interest, because
they are frequent complications that reduce the quality life
of the patient, may worsen symptoms such as fatigability,
weakness, nausea, and may be important factors involved
in the pathophysiology of inﬂammatory response [1, 2, 13].
Iron deﬁciency mainly results from chronic blood loss in
the intestine, but iron malabsorption due to inﬂammatory
activity may also contribute [14]. Complex changes in iron
metabolism,mediatedbycytokinessuchasIL-1,IL-6,IFN-γ,
andTNF-α, occuralsoin chronic inﬂammatorydisease, with
reducedreleaseofironfrommacrophagestotransferrin. The
classical biochemical picture includes both low serum iron
and transferrin saturation level, and elevated serum ferritin
concentrations [14].
In veterinary literature, mild anemia is reported in
12% of dogs with IBD [10], in agreement with our result
where mild microcytic or normocytic anemia was found
in 18% of dogs. Microcytic anemia is often related to iron
deﬁciency due to chronic hemorrhage [15, 16], but, in our
study, none of the anemic dogs had a positive fecal occult
blood test or very low iron concentration or high TIBC
concentration. These ﬁndings rule out an IDA. In dogs with
occultfecalbloodanemia,lowironorferritinconcentrations4 Veterinary Medicine International
werenotdetected,whereaserythrocytosisandreticulocytosis
observed in these cases support an erythroid compensatory
response. On the other hand, a single positive occult fecal
blood test does not provide information about the duration
of intestinal hemorrhage.
The MCV may be slightly decreased in association to
chronic inﬂammatory disease [16]. In addition, the MCV
appearsfrequentlyslightlybelowthereferencerangeandHct
isfrequentlywithinthereferencerangeoronlyamildanemia
is present [15]. In our study, microcytosis without anemia
was the more frequent ﬁnding than anemia and, most of
the dogs had an MCV at the lower end of the reference
range. The MCV is not a sensitive parameter to detect iron
bioavailability. Steinberg and Olver [17] reported that the
evaluationofbothreticulocyteHgbcontent(CHr)andMCV
(rMCV) would be more useful in evaluating iron-dependent
erythropoiesis in dogs. Both low rMCV and CHr may occur
in the earlier stages of iron depletion and may therefore be a
sensitive markers of early iron unavailability.
The iron values at the lower end of the reference range,
normal ferritin, normal or slightly low TIBC, and high CRP
concentration support the diagnosis of anemia of chronic
disease (ACD). The pathogenesis of ACD is mediated by
cytokines produced during inﬂammation and resulted from
iron sequestration, inducing reduction of erythrocyte half-
life decline and erythropoietic response [16]. Serum ferritin
and UIBC are acute-phase proteins that, in neoplastic and
inﬂammatory diseases, may be increased and decreased,
respectively. This feature likely decreases the sensitivity to
detect iron deﬁciency. The use of others markers is conve-
nient,suchasserumtransferrinreceptorinhumanmedicine,
to characterize iron abnormalities [18–20]. Although Jergens
and others [11] pointed out that CRP was a marker of
disease severity in dogs with CE, in the present study CRP
concentrations were not correlated with CIBDAI. On the
other hand, this ﬁnding agrees with Allenspach and others
[21], but more studies are needed to verify the role of CRP in
canine CE.
Although clinical improvement or complete recovery
from symptoms was present in all dogs, and they were
unrelated to CIBDAI or type of CE, erythrocyte parameters
at posttreatment evaluation were not so improved as well.
In addition, polychromasia, anisocytosis, and Howell Jolly
bodies in RBCs observed in the blood smear, all together
signs of bone marrow activation, were identiﬁed both in pre-
and posttreatment evaluation, and CRP concentrations were
not reduced signiﬁcantly.
It might be speculated that mild subclinical intestinal
wall inﬂammation, not detectable by CIBDAI application,
persists also in dogs recovered from symptoms. This hypoth-
esis may be supported by several studies [21–23]w h e r e
in cases of CE no signiﬁcant changes were observed at
posttreatment in the severity of histopathologic lesions in
the face of an improvement of both clinical signs and
endoscopical ﬁndings.
Alternatively, considering that typical hematologic
changes do not occur until late in severe iron abnormality
[18], it is possible that anemia, microcytosis, and
thrombocytosis needed more than the six months time
of our study to improve. The signiﬁcant increase of
iron, UIBC, and TIBC serum concentrations revealed
an improvement of iron metabolism with therapy. The
observed modiﬁcations of iron and UIBC do not increase
signiﬁcantly the transferrin saturation post therapy, because
it derives from the ratio iron/TIBC. Harvey and others [24]
reported that steroid therapy may result in increased serum
iron concentrations in dogs, but we did not observe any
diﬀe r e n c e sa m o n gS R Dg r o u pv e r s u sF R Da n dA R Dg r o u p s .
In the present study, 31.8% of dogs showed thrombocy-
tosis, whereas in a previous investigation Craven and others
[10] observed it only in 7% of dogs. Thrombocytosis can
be observed in several disorders including bone marrow
neoplastic condition, even if rarely reported, infectious and
inﬂammatory disorders, several neoplasia, acute bleeding or
hemolysis, and iron deﬁciency [7]. Thrombopoietic growth
factors including IL-6, TNF-α, and thrombopoietin have
been implicated as causes of reactive thrombocytosis [7, 25].
In man, high platelet count and a low MPV are well-
r e c o g n i z e dm a r k e r so fa c t i v eI B Da c t i v i t ya n dp r o b a b l y
represent a nonspeciﬁc response to inﬂammation [26], but
iron abnormalities can also be involved, although the mech-
anism causing reactive thrombocytosis in iron deﬁciency
anemia is currently not well understood [7]. In our small
study, no signiﬁcant diﬀerences were found in serum iron
concentration in dogs with or without thrombocytosis, but
moreresearchisneededtounveilthemechanismresponsible
for the increase of platelets in dogs with CE. In human
medicine, high plasma thrombopoietin concentrations were
found in patients with ulcerative colitis and Crohn’s disease
[27], and both the procoagulant state and microvascular
thrombosis may play a role in the pathogenesis of IBD [28].
In human medicine, a low MPV is associated with active
IBD [27, 29], but in the present study microthrombocytosis
was not revealed. In our study, no posttreatment signiﬁcant
reductionofplateletcountswasobservedandpersistentmild
intestinal wall inﬂammation might be the cause as suggested
for the erythrocyte parameters. Finally, no signiﬁcant corre-
lations in platelets counts and MPV among CIBDAI versus
FRD, ARD, and SRD were noted.
5. Conclusions
The signiﬁcant modiﬁcations of iron metabolism in CE
could encourage the evaluation of iron and UIBC serum
concentrations,asnonspeciﬁcmarkersofinﬂammation. The
use of more sensitive and speciﬁc markers of iron disorders,
such as transferrin soluble receptors in human medicine
[20], could be valuable in the future. The ﬁndings of this
survey could stimulate a detailed approach to RBC and
PLT features using more sophisticated laser cell counter to
evaluate iron-dependent erythropoiesis in dogs.
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